A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer)

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 254-258

  Kenmotsu, Hirotsugu ^a   Niho, Seiji ^b   Ito, Takeo ^c   Ishikawa, Yuichi ^d   Noguchi, Masayuki ^e   Tada, Hirohito ^f   Sekine, Ikuo ^g   Watanabe, Shun ichi ^h   Yoshimura, Masahiro ⁱ   Yamamoto, Nobuyuki ^a   Oshita, Fumihiro ^j   Kubota, Kaoru ^k   Nagai, Kanji ^b  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c Division of Pulmonary Medicine Kuroki Memorial Hospital   (Japan)

^d CANCER INSTITUTE   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f OSAKA CITY GENERAL HOSPITAL   (Japan)

^g CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ HYOGO CANCER CENTER   (Japan)

^j KANAGAWA CANCER CENTER   (Japan)

^k NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

more..

Author keywords

Adjuvant chemotherapy; High grade neuroendocrine carcinoma; Large cell neuroendocrine carcinoma; Lung cancer; Small cell carcinoma

Indexed keywords

CISPLATIN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HIGH GRADE NEUROENDOCRINE CARCINOMA; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG LOBECTOMY; LUNG SMALL CELL CANCER; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; VOMITING; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, NEUROENDOCRINE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG NEOPLASMS; LUNG RESECTION; MORTALITY; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NEUROENDOCRINE; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; PILOT PROJECTS; PNEUMONECTOMY; YOUNG ADULT;

EID: 84901953872     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.007     Document Type: Article

References (29)

1. Travis W.D., Linnoila R.I., Tsokos M.G., Hitchcock C.L., Cutler G.B., Nieman L., et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991, 15(June (6)):529-553.
2. Cerilli L.A., Ritter J.H., Mills S.E., Wick M.R. Neuroendocrine neoplasms of the lung. Am J Clin Pathol 2001, 116(December (Suppl.)):S65-S96.
3. Marchevsky A.M., Gal A.A., Shah S., Koss M.N. Morphometry confirms the presence of considerable nuclear size overlap between small cells and large cells in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 2001, 116(October (4)):466-472.
4. Asamura H., Kameya T., Matsuno Y., Noguchi M., Tada H., Ishikawa Y., et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006, 24(January (1)):70-76.
5. Rossi G., Cavazza A., Marchioni A., Longo L., Migaldi M., Sartori G., et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005, 23(December (34)):8774-8785.
6. Sorensen M., Pijls-Johannesma M., Felip E. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(May (Suppl. 5)):v120-v125.
7. Simon G.R., Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(September (3 Suppl.)):324S-339S.
8. Tsuchiya R., Suzuki K., Ichinose Y., Watanabe Y., Yaumitsu T., Ishizuka N., et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer StudyGroup Trial (JCOG9101). J Thorac Cardiovasc Surg 2005, 129(May (5)):977-983.
9. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346(January (2)):85-91.
10. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18(February (2)):317-323.
11. Shore D.F., Paneth M. Survival after resection of small cell carcinoma of the bronchus. Thorax 1980, 35(November (11)):819-822.
12. Sorensen H.R., Lund C., Alstrup P. Survival in small cell lung carcinoma after surgery. Thorax 1986, 41(June (6)):479-482.
13. Prasad U.S., Naylor A.R., Walker W.S., Lamb D., Cameron E.W., Walbaum P.R. Long term survival after pulmonary resection for small cell carcinoma of the lung. Thorax 1989, 44(October (10)):784-787.
14. Shah S.S., Thompson J., Goldstraw P. Results of operation without adjuvant therapy in the treatment of small cell lung cancer. Ann Thorac Surg 1992, 54(September (3)):498-501.
15. Coolen L., Van den Eeckhout A., Deneffe G., Demedts M., Vansteenkiste J. Surgical treatment of small cell lung cancer. Eur J Cardiothorac Surg 1995, 9(2):59-64.
16. Stahel R., Thatcher N., Fruh M., Le Pechoux C., Postmus P.E., Sorensen J.B., et al. 1st ESMO consensus conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol 2011, 22(September (9)):1973-1980.
17. Davis S., Crino L., Tonato M., Darwish S., Pelicci P.G., Grignani F. A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer. Am J Clin Oncol 1993, 16(April (2)):93-95.
18. Iyoda A., Hiroshima K., Moriya Y., Takiguchi Y., Sekine Y., Shibuya K., et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006, 82(November (5)):1802-1807.
19. Lara P.N., Natale R., Crowley J., Lenz H.J., Redman M.W., Carleton J.E., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009, 27(May (15)):2530-2535.
20. Hanna N., Bunn P.A., Langer C., Einhorn L., Guthrie T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006 May 1, 24(13):2038-2043.
21. Jiang J., Liang X., Zhou X., Huang L., Huanz R., Chu Z., et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010, 5(June (6)):867-873.
22. Sun J.M., Ahn M.J., Ahn J.S., Um S.W., Kim H., Kim H.K., et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?. Lung Cancer 2012, 77(August (2)):365-370.
23. Fujiwara Y., Sekine I., Tsuta K., Ohe Y., Kunitoh H., Yamamoto N., et al. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol 2007, 37(July (7)):482-486.
24. Igawa S., Watanabe R., Ito I., Murakami H., Takahashi T., Nakamura Y., et al. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer 2010, 68(June (3)):438-445.
25. Niho S., Kenmotsu H., Sekine I., Ishii G., Ishikawa Y., Noguchi M., et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol 2013, 8(July (7)):980-984.
26. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352(June (25)):2589-2597.
27. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350(January (4)):351-360.
28. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7(September (9)):719-727.
29. Natale R.B., Lara P.N., Chansky K., Crowley J.J., Jett J.R., Carleton J.E., et al. S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). ASCO Meeting Abstract. J Clin Oncol 2008, 26(May (Suppl. 15)):7512.